IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Plus Capecitabine or Capecitabine Plus Docetaxel in the Treatment of Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2016
At a glance
- Drugs Ixabepilone (Primary) ; Capecitabine; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms IXTEND
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 15 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Jan 2010 Planned end date changed from 1 Aug 2012 to 1 Mar 2010 as reported by ClinicalTrials.gov.